Securities Code: 688105 Securities abbreviation: Novizan Announcement No.: 2023-002.

Nanjing Nuoweizan Biotechnology Co., Ltd.

2022 Annual Performance Express Announcement

The Board of Directors and all Directors of the Company warrant that the contents of this announcement do not contain any false records, misleading statements or

and bear legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

The main financial data for 2022 contained in this announcement are preliminary accounting data and have not been audited by an accounting firm. The specific data are subject to the 2022 periodic report of Nanjing Nuoweizan Biotechnology Co., Ltd. (hereinafter referred to as the "Company"). Investors are reminded to pay attention to investment risks.

Key Financial Data and Indicators for 1. 2022

Unit: RMB Yuan

Changes in the same period of the previous year (%)

Total operating income 3,575,659,257.50 1,868,627,293.06 91.35

Research and Development Expenses 396,106,955.72 230,321,525.49 71.98

Operating profit 690,726,942.13 771,138,247.61 -10.43

Total profit 674,436,430.07 764,445,018.95 -11.77

651,380,605.72 678,289,569.04 attributable to owners of the parent -3.97

Net profit

Attributable to owners of the parent company

Net 643,086,493.12 643,934,426.67 net of non-recurring gains and losses -0.13

Profit

Basic earnings per share (RMB) 1.63 1.87 -12.83

Weighted average ROE 14.60 per cent 40.49 per cent down 25.89 percentage points

Increase or decrease at the end of the reporting period at the beginning of the reporting period (%)

Total Asset 6,017,945,073.75 4,607,119,884.54 30.62

Owners' 4,666,137,068.58 4,127,289,969.06 13.06 attributable to the parent company

Equity

Share capital (10,000 shares) 40,001.00 40,001.00 0.00

11.67 10.32 13.03 attributable to owners of the parent company

Net assets per share (yuan)

Note: 1. The beginning of the reporting period is the same as the statutory disclosure at the end of the previous year. 2. The above financial data and indicators are based on unaudited consolidated financial statements, and the final results are based on the Company's 2022 annual report. 3. If there is a tail difference in the above data, it is four rounding

5.

Securities Code: 688105 Securities abbreviation: Novizan Announcement No.: 2023-002.

Statement of 2. results of operations and financial position

(I) operation and financial position

During the reporting period, the company achieved operating income of 3,575.6593 million billion yuan, an increase of 91.35 percent over the same period last year; net profit attributable to owners of the parent company was 651.3806 million billion yuan, down 3.97 percent from the same period last year; and net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 643.0865 million billion yuan, down 0.13 percent from the same period last year.

At the end of the reporting period, the company's total assets were 6,017.9451 million billion yuan, an increase of 30.62 over the beginning of the reporting period; the owner's equity attributable to the parent company was 4,666.1371 million billion yuan, an increase of 13.06 over the beginning of the reporting period.

Main reasons for changes in (II) operating results

During the reporting period, the Company realized sales revenue from conventional business (covering non-new crown business such as scientific research reagents, sequencing reagents, diagnostic raw materials, diagnostic reagents and instruments, CRO services, etc.) of approximately RMB 1.014 billion, an increase of approximately 41.19 relative to the same period in 2021, while overcoming the adverse factors caused by the new crown virus infection, during the reporting period, it was mainly promoted by factors such as the gradual return to normalization of teaching and research and development of downstream customers and the overall operation of enterprises, the further improvement of the company's research and development efficiency, the steady increase in the scale and share of relevant market segments, and the rapid growth of growth business. During the reporting period, the company realized the sales revenue of the new crown testing business (including diagnostic raw materials and terminal testing reagents) of about 2.562 billion yuan, an increase of about 122.78 relative to the same period in 2021, mainly due to the company's new crown antigen testing kit approved for sale in China during the reporting period, the new crown nucleic acid testing raw materials downstream demand for stable growth.

During the reporting period, the company continued to increase investment in R & D, management and marketing team building, and the scale of personnel grew rapidly. At the same time, it increased market expansion and publicity according to business needs. During the reporting period, the company's research and development expenses increased by 71.98 over the same period last year, management expenses increased by 62.55 over the same period last year, and sales expenses increased by 63.69 over the same period last year.

Since the company's new crown testing related biological raw materials and terminal testing reagent products were approved for listing, the purchase and reserve of related production raw materials, capacity construction, sales price, etc. have been significantly affected by the new crown prevention and control policy and market supply and demand. In December 2022, after the adjustment of China's new crown prevention and control policy, the domestic market demand for new crown antigen testing reagents and prices decreased rapidly after a short-term sharp increase, resulting in the risk of impairment of the Company's new crown testing related assets. Based on the principle of prudence, the Company has provided for asset impairment losses in accordance with the Enterprise Accounting Standards and the Company's accounting policies. Up to now, the company's relevant impairment test and 2022 annual report audit work is still in progress, in order to ensure the accuracy and rigor of the relevant data, the final amount of the provision will be determined after the completion of the audit work of the annual audit institution.

Securities Code: 688105 Securities abbreviation: Novizan Announcement No.: 2023-002.

Reasons for changes in the increase or decrease of more than 30 per cent in the (III) of related items

During the reporting period, the Company's operating income increased by 91.35 over the same period of the previous year, mainly due to the overall growth of customer demand for conventional business, the improvement of the Company's overall competitiveness, the growth of growth business and the greater downstream demand for the new crown testing business.

During the reporting period, the company's R & D expenses increased by about 71.98 over the same period of the previous year, mainly due to the company's continuous increase in R & D investment, expansion of R & D teams, increase in the number of R & D projects and subsequent increase in R & D investment during the reporting period.

At the end of the reporting period, the company's total assets increased by 30.62 compared with the beginning of the period, mainly due to the expansion of the company's production and operation scale during the reporting period, the simultaneous increase in sales credit payments, inventory reserves, production of office equipment and plants, foreign investment and other assets.

3. Risk Alert

The main financial data for 2022 contained in this announcement are preliminary accounting results, which have not been audited by an accounting firm, and may differ from the final data disclosed in the company's 2022 annual report. Please refer to the 2022 annual report data disclosed by the company. Investors should pay attention to investment risks.

It is hereby announced.

Nanjing Nuoweizan Biotechnology Co., Ltd.

Board of Directors

28 February 2023